“Oncolytic Virus” (Seprehvir®, Seprehvec®)

Sorrento’s oncolytic viral vector asset is a modified version of the common human herpes simplex virus (HSV-1). Seprehvir® has been designed with the ability to specifically destroy tumor cells while also stimulating anti-tumor patient immune responses. As part of its global clinical development program, Seprehvir has been administered to over 100 adult and pediatric patients in a variety of solid tumors including glioblastoma, mesothelioma, melanoma, head and neck cancer, pediatric sarcomas and pediatric neuroblastomas.

We believe that a key advantage of Seprehvir, as compared to other HSV based oncolytic therapies, is that it has been safely administered intravenously, intratumorally and by loco-regional infusion to specifically tailor the therapy to a patients’ specific cancer.

The Seprehvec® asset is a future generation project which aims to provide additional therapeutic options and can rapidly generate novel oncolytic immunotherapies:

  • “targeted” specifically to certain types of tumor cells.
  • “armed” with additional genes to enhance the destruction of those tumor cells.
  • multi-functional “targeted” and “armed” variants with enhanced cell killing and immuno-stimulatory activities.

Oncolytic Viral Immunotherapies

Oncolytic Viral Immunotherapies

Immuno-Oncology Assets

G-MABS CAR-T ADCs iTAbs Oncolytic Virus